Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04847232 · ClinicalTrials.gov registry record · Phase 3
Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)
A Phase 3 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 3
- Development phase
- 2,690
- Enrollment target
NCT04847232 is a Phase 3 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 2,690 participants.
The verdict
NCT04847232, a Phase 3 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 2,690 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of Sodium Zirconium Cyclosilicate (SZC) on arrhythmia-related cardiovascular outcomes in participants on chronic hemodialysis with recurrent hyperkalemia.
Interventions
- DRUG Sodium Zirconium Cyclosilicate (SZC)
- DRUG SZC Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,690 participants |
| Start Date | 2021-04-30 |
| Est. Completion | 2024-03-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04847232
The ClinicalTrials.gov registry entry for NCT04847232 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 2,690 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sodium Zirconium Cyclosilicate (SZC) is the first listed.
NCT04847232 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04847232 about?
NCT04847232 is a clinical study titled "Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)". The purpose of this study is to evaluate the effect of Sodium Zirconium Cyclosilicate (SZC) on arrhythmia-related cardiovascular outcomes in participants on chronic hemodialysis with recurrent hyperkalemia.
What is the current status of trial NCT04847232?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 2,690 participants. The study started on 2021-04-30. Estimated completion is 2024-03-07.
What interventions are being tested in trial NCT04847232?
The interventions under investigation include: Sodium Zirconium Cyclosilicate (SZC) (DRUG), SZC Placebo (DRUG).
Who is sponsoring clinical trial NCT04847232?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.